Biological Implants Market Report Scope & Overview:

The Biological Implants Market was valued at USD 9.48 Billion in 2025 and is expected to reach USD 17.98 Billion by 2035, growing at a CAGR of 6.61% from 2026–2035.

The biological implants industry is continuing its evolution in view of the demographic, clinical, and technological convergence. The increasing prevalence of chronic illnesses such as cardiovascular, orthopedic, and dental disorders, along with the aging population which increasingly needs medical interventions, becomes the key reason for market growth. Biological implants, which consist of biocompatible materials like collagen, bone, and engineered tissues, provide better integration with the human body and less chances of rejection compared with artificial materials, hence becoming more preferable for older people whose immune system tends to be weakened.

According to the World Health Organization, cardiovascular diseases are responsible for about 32 percent of deaths around the world each year, thus the importance of having biological innovations in cardiovascular implants cannot be understated. The CDC along with other United States governmental organizations allocated more than USD 300 million in 2023 towards prevention of heart diseases and strokes.

Market Size and Forecast

• Market Size in 2026E: USD 10.10 Billion

• Market Size by 2035: USD 17.98 Billion

• CAGR: 6.61% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

Biological Implants Market Trends

• Tissue engineering advancements are improving the biocompatibility and performance of biological implants while reducing immunological rejection across orthopedic, dental, and cardiovascular applications.

• Evolving regulatory standards are strengthening safety, quality, and manufacturing requirements for collagen-based implants and extracellular matrix scaffold products.

• Growing adoption of allografts is driven by advances in tissue banking, sterilization technologies, and donor matching that improve implant availability and outcomes.

• Integration of artificial intelligence, 3D printing, and advanced extracellular matrix scaffolds is accelerating innovation in personalized biological implant development.

• Smart biological implants with embedded sensing technologies are expanding clinical applications by enabling real-time monitoring and improved post-implantation patient management.

The U.S. Biological Implants Market Outlook

The U.S. Biological Implants Market was valued at approximately USD 4.10 Billion in 2025 and is expected to reach approximately USD 7.70 Billion by 2035, growing at a CAGR of approximately 6.51%.

The USA is one of the major players in the international biological implants industry owing to its highly sophisticated healthcare system, huge government spending in healthcare sector, and fast adoption of technology in different forms of biological implants such as soft tissue implants, cardiovascular biological implants, and orthopedic biological implants. The health care expenditure of USA was estimated at USD 4.1 trillion in the year 2020 by Centers for Medicare & Medicaid Services. Major investments in biocompatible implant materials, tissue engineering, and regenerative biological materials signify the dominance of USA in biological implants market.

June 2024 saw Bioretec Ltd. announce the success of U.S. clinical trials on its biodegradable RemeOs trauma screw, which showed that it was able to achieve bone fracture healing, surgical compatibility, and bone regeneration without the need for another operation to remove the implant. This is a step forward in biological implants for orthopedics.

Biological Implants Market Segment Analysis

• By Product, the xenografts segment dominated the biological implants market with a 49% revenue share in 2025, while the allografts segment is expected to demonstrate the fastest growth.

• By Mode of Administration, the surgical segment dominated the biological implants market with a 56% revenue share in 2025, and is also expected to grow at the fastest rate.

• By Formulation, the solid implants segment dominated the biological implants market with a 42.8% revenue share in 2025, while the composite implants segment is expected to demonstrate the fastest growth during the forecast period.

• By Application, the soft tissue implants segment led the biological implants market in 2025, while the cardiovascular implants segment is expected to register the fastest growth.

By Product, xenografts dominate, allografts register the fastest growth

The share of xenografts in the biological implants market was 49% in 2025, which is the highest amongst products, owing to their availability and advancement in biocompatible implant material technology. The usage of biological implants derived from animals has increased significantly in recent times, especially in cases involving soft tissue, dental implants, and cardiovascular procedures because of the dearth of human tissue. Due to advancement in tissue engineering technology, xenografts can now be made to resemble human tissue.

It is estimated that allografts will grow at the highest rate during the forecast period on account of improvements in the field of tissue banking, sterilization, and donor matching technologies. Allografts derived from human donors are gaining popularity for bone reconstruction procedures, biological grafts, and orthopedic biological implants; the market leaders have launched novel products that include allografts, such as T3 PRO Tapered Implant and Encode Emergence Healing Abutment, FDA approved allograft products of ZimVie.

By Mode of Administration, surgical implantation dominates the market

The surgical segment accounted for 56% of the biological implants market in 2025 and is expected to sustain the fastest growth rate over the forecast period. This predominance is driven by the rising volume of surgical procedures for orthopedic, cardiovascular, and dental biological implants, alongside the demonstrated efficacy of surgical implant biomaterials in complex clinical situations. With developments in minimally invasive surgery techniques, robotic surgery, and biocompatible implant materials, the outcomes for patients have continued to improve and their recovery time shortened, thus making surgical implantation the ideal method of delivery.

There will be regulatory support to ensure that this market grows further, as shown by the FDA's guidelines for 2024 regarding sterilization sites modifications which ensure there is continuous supply of surgical implant biomaterials. The Australian TGA's regulations on the amendment of Good Manufacturing Practices for therapeutic goods in September 2024 have made standards even higher in this segment.

By Application, soft tissue implants lead current demand, cardiovascular implants register the fastest growth

Biological implants based on soft tissues were leading the biological implants market by application in 2025, owing to the growing instances of injuries and reconstruction surgery and cosmetic surgery across the world. Advancements in biocompatible implant materials and tissue engineering have increased the safety, effectiveness, and durability of biological implants made from soft tissue, thereby making them more preferred among patients and doctors. The regulatory environment is favorable towards adoption of biological implants in orthopedics due to De Novo approval for smart orthopedic implants like Zimmer Biomet's Persona IQ by FDA of the U.S.

The implants that are biological in nature with respect to the cardiovascular system are expected to show the fastest growth rate during the forecasted period due to the increasing burden of cardiovascular diseases worldwide and also because of the adoption of minimally invasive techniques. The new FDA guidance released in 2024 for accelerated sterilization of Class III devices ensures an adequate supply of such critical implants. The updated safety regulations by the European Medicines Agency are geared towards ensuring high-quality products.

Regional Analysis

North America Biological Implants Market Insights

North America, led by the United States, dominated the global biological implants market in 2025, with a 51% market share. Advanced healthcare infrastructure, substantial government healthcare expenditure, and rapid adoption of novel technology across soft tissue, cardiovascular, and orthopedic biological implants continue to explain this regional supremacy. According to the Centers for Medicare & Medicaid Services, the health expenditure by the United States is estimated at $4.1 trillion, indicating significant investments in biocompatible implant materials, tissue engineering, and regenerative biological materials.

The fact that there are large biological implant manufacturers in the region such as Stryker, Medtronic, and Johnson & Johnson further indicates the dominance of the regional market. According to the Centers for Disease Control and Prevention, 1 in every 20 adult Americans aged 20 years and older have coronary artery disease.

Europe Biological Implants Market Insights

The Europe region accounts for a considerable portion of the biological implants market worldwide due to the aging population and the occurrence of various degenerative and chronic illnesses such as osteoporosis and cardiovascular diseases. The region has stringent regulations regarding the biological implants thanks to the guidelines set up by the European Medicines Agency. These regulations ensure the safety and effectiveness of biological implants such as biological mesh implants, collagen-based implants, and extracellular matrix scaffolds.

Demand for minimally invasive procedures continues to be relatively high due to innovations in surgical implant biomaterials and favorable insurance coverage. Germany, France, and the UK remain at the forefront in terms of regional adoption of advanced cardiovascular, soft tissue, and dental biological implants.

Asia Pacific Biological Implants Market Insights

The Asia Pacific region is expected to have the fastest growth rate at a CAGR of 7.34%. This will be due to the increasing expenditure on health care, the prevalence of chronic diseases, and the improvement in health care infrastructure. The main contributors to this growth include China, Australia, and India.

However, the Asia Pacific Orthopedic Association, whose membership exceeds 65,000 people, continues its advocacy for biologics use in orthopedics and advanced surgical techniques in the region. In 2022, Australia had 29.6 deaths due to chronic obstructive pulmonary disease per 100,000 people, which emphasizes the increasing significance of biological implants in degenerative disease management.

MEA & Latin America Biological Implants Market Insights

In the Middle East and Africa, there is increasing uptake of biological implants due to increased spending on health care infrastructure and awareness about improved treatment options. In the region, Saudi Arabia takes the lead regarding demand for biological implants due to continued efforts in modernizing the country's health care system, alongside contributions from South Africa.

The region of Latin America is also on a similar path of growth driven by Brazil, due to increase in the number of healthcare facilities and increasing cases of reconstructive and orthopedic surgeries which will result in driving demand for biological implants. The two regions are still smaller markets than that of North America, Europe, and Asia-Pacific, but further investments in healthcare infrastructure will fuel growth.

Market Dynamics

Growth Drivers: Rising geriatric population and chronic disease burden accelerate implant adoption

The rapidly increasing global elderly population, combined with the growing frequency of chronic disease, is significantly increasing biological implant adoption worldwide. According to the World Health Organization, there will be 1.4 billion people aged 60 and above by 2030, more than double the figure in 2020. The elderly are vulnerable to degenerative diseases such as osteoarthritis, cardiovascular disease, and diabetes, which often need surgery involving the implantation of biological implants.

More than 528 million people worldwide suffer from osteoarthritis, leading to joint degeneration and necessitating hip, knee, or spine implants. According to the CDC, about 54 million people in the U.S. suffer from arthritis alone, a number expected to increase further as the population grows older. Biological implants provide good compatibility with human tissues and are less likely to cause rejection than their synthetic counterparts.

Restraints: Post-operative risks and regulatory complexity delay market expansion

Approval processes that take up to 7 to 10 years for the introduction of new implants and an FDA recall rate that rises at 12% per year since 2020 continue to hinder the market growth. Recurrence of lawsuits regarding metal-on-metal hip implant and pacemaker cybersecurity threats has shaken the faith of patients since 34 percent of American adults are unsure about the safety of implants.

Problem of biocompatibility persists since 15 percent of polymeric implants provoke immunogenic responses resulting in revision operations that are 2.3 times more costly than the initial operation. Despite the changes proposed for ISO 13485 in 2023 which are geared towards establishing uniformity in quality management practices, the issue of fragmented regulation and liability issues across the globe remain a barrier to small firms in niche markets such as pediatric implants.

Opportunities: Regenerative biological materials and smart implant technology create expanding growth avenues

Continued advancement in regenerative biological materials, including bioresorbable implants and next-generation extracellular matrix scaffolds, represents a substantial growth opportunity across orthopedic, cardiovascular, and soft tissue applications. Regulatory support for accelerated approval pathways, including expedited sterilization guidance for Class III devices, continues to shorten development timelines for innovative biological implant technology.

The integration of smart implant technology, including sensor-enabled devices capable of real-time patient monitoring, presents a further meaningful opportunity for manufacturers positioned to combine biological implant materials with digital health capability. As artificial intelligence and 3D printing technology continue to mature, companies developing genuinely differentiated, patient-specific biological implant solutions stand to capture growing demand throughout the forecast period.

Recent Developments:

• 2023: In January 2023, Arthrex received FDA approval for its TightRope implant for pediatric use, the first and only fixation device for anterior cruciate ligament injuries certified for pediatric patients.

• 2024: In June 2024, Bioretec Ltd. announced successful U.S. clinical outcomes for its biodegradable RemeOs trauma screw, demonstrating complete fracture healing and bone replacement without requiring removal surgery.

• 2024: In July 2024, Health Canada revised its Good Manufacturing Practices for biologics in line with international standards to improve control of biologic grafts and regenerative biological materials.

Biological Implants Market Key Players are:

• Stryker Corporation

• Medtronic plc

• Zimmer Biomet Holdings, Inc.

• Smith+Nephew plc

• Johnson & Johnson

• Baxter International Inc.

• Edwards Lifesciences Corporation

• Integra LifeSciences Holdings Corporation

• Artivion, Inc.

• RTI Surgical

• LifeCell International Pvt. Ltd.

• Vericel Corporation

• Organogenesis Holdings Inc.

• Geistlich Pharma AG

• CONMED Corporation

• Alphatec Holdings, Inc.

• NuVasive, Inc.

• BioTissue

• Osteotec Limited

• AbbVie Inc.

Biological Implants Market Report Scope: